Inspire(US:INSP) Newsfile·2025-11-17 20:18Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. for securities fraud following a significant stock drop due to alleged violations of federal securities laws [2][4]. Company Overview - Inspire Medical Systems, Inc. specializes in developing and manufacturing implantable medical devices for the treatment of sleep apnea, with its latest product being the Inspire V, which received FDA approval on August 2, 2024 [5]. Allegations and Issues - The lawsuit claims that Inspire misled investors by assuring them that all necessary steps were taken for the launch of Inspire V, which was supposed to meet high demand. However, the company failed to adequately prepare clinicians and payors, leading to significant delays in adoption [6][7]. - The launch of Inspire V faced an "elongated timeframe," resulting in a reduction of the 2025 earnings per share guidance by over 80%. Contributing factors included incomplete training at implanting centers and poor demand due to excess inventory of older devices [8]. Stock Performance - Following the announcement of the delays, Inspire's stock price plummeted by $42.04 per share, a decrease of more than 32%, dropping from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [9].